These are illustrated in figure 18
Its hard to think, if its 2030, and we have many of these medicines that weve proven the benefits for chronic diseases and the government said its worth it after this two-year pilot theyre doing its hard to think of too many employers who would say, Thats not for me, Ricks told me
Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data
Desiree Sierra-Velez, the Centers medical director
If the drugs are directly both improving weight reduction and cancer reduction, then we need to double down. Ganta wonders the same thing about the drugs apparent positive effects on several conditions, from dementia to sleep apnea: Is it that obesity is causing or contributing to the problem [and that weight loss is causing the improvement], or is the medication directly having an impact through a different mechanism? She hopes there will be more research to parse this out in the years to come
